FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
NUDT21 regulates fibroblast senescence and is significantly decreased in aged and fibrotic lungs, impacting IPF progression. Alternative polyadenylation (APA) and NUDT21 downregulation enhance STAT3 ...
L uis Garza, a physician-scientist at Johns Hopkins University School of Medicine for over a decade, noticed a common issue when treating people with limb amputations at his clinic. They often had ...
FibroBiologics, Inc., a clinical-stage biotechnology company specializing in fibroblast-based therapies, announced that CEO Pete O’Heeron will present a company update at the BIO International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results